NEW YORK (360Dx) – San Francisco-based Notable Labs today announced that it has raised $10 million in Series A funding, which it will put toward building its technology platform and team, as well as clinical feasibility studies related to blood cancers.

The firm provides a drug-testing service for oncologists identifying treatment options for blood-cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sep
27

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Oct
12
Sponsored by
PierianDx

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers. 

Oct
17

This webinar will discuss the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.